Regorafenib Induces DNA Damage and Enhances PARP Inhibitor Efficacy in Pancreatic Ductal Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Dec 20

PMID 39707244

Authors

Thao D Pham

Jeffrey H Becker

Anastasia E Metropulos

Nida Mubin

Christina Spaulding

David J Bentrem

Hidayatullah G Munshi

Affiliations

Soon will be listed here.

Abstract

Background: There is increasing interest in enhancing the response of the PARP inhibitor olaparib, which is currently approved for pancreatic ductal adenocarcinoma (PDAC) patients with defects in DNA damage repair associated with germline BRCA1/2 mutations. Moreover, agents that can mimic these defects in the absence of germline BRCA1/2 mutations are an area of active research in hopes of increasing the number of patients eligible for treatment with PARP inhibitors. The extent to which regorafenib, an FDA-approved tyrosine kinase inhibitor, can be used to enhance the efficacy of PARP inhibitors in PDAC cells without known BRCA1/2 mutations remains to be investigated.

Methods: Comet assay, cell cycle analysis, western blotting, and immunofluorescent detection of H2AX were used to evaluate the extent to which regorafenib induces DNA damage in PDAC cell lines. The effects of regorafenib, either alone or in combination with PARPi inhibitors, on PDAC cell death were assessed by Annexin V/PI co-staining assay in cell lines and by immunohistochemistry staining for cleaved caspase-3 in mouse tumors and in ex vivo slice cultures of human PDAC tumors. Flow cytometry-based analysis was used to evaluate the ability of regorafenib to reprogram PDAC tumor microenvironment.

Results: We now show that regorafenib, a tyrosine-kinase inhibitor with efficacy in several gastrointestinal malignancies, can enhance the response of olaparib in pancreatic cancer. While regorafenib induces DNA damage and limits the ability of PDAC cells to resolve the damage, regorafenib by itself does not induce apoptosis. However, regorafenib in combination with olaparib further induces DNA damage in vitro, in tumor-bearing mice, and in ex vivo slice cultures of human PDAC tumors, resulting in increased apoptosis compared to olaparib alone. Notably, we show that the efficacy of the combination treatment is not dependent on cytolytic T cells.

Conclusions: Together, these findings demonstrate that regorafenib can attenuate DNA damage response and potentiate the efficacy of PARP inhibitors in PDAC tumors.

References

Davies A, Masson J, McIlwraith M, Stasiak A, Stasiak A, Venkitaraman A . Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell. 2001; 7(2):273-82. DOI: 10.1016/s1097-2765(01)00175-7. View

Mehta M, Griffith J, Panneerselvam J, Babu A, Mani J, Herman T . Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. Int J Radiat Biol. 2020; 97(8):1109-1120. PMC: 7882427. DOI: 10.1080/09553002.2020.1730012. View

Tseng L, Lau K, Chen J, Chu P, Huang T, Lee C . Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model. Exp Cell Res. 2023; 429(1):113652. DOI: 10.1016/j.yexcr.2023.113652. View

Pham T, Spaulding C, Shields M, Metropulos A, Shah D, Khalafalla M . Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity. JCI Insight. 2022; 7(9). PMC: 9090262. DOI: 10.1172/jci.insight.152731. View

Gyori B, Venkatachalam G, Thiagarajan P, Hsu D, Clement M . OpenComet: an automated tool for comet assay image analysis. Redox Biol. 2014; 2:457-65. PMC: 3949099. DOI: 10.1016/j.redox.2013.12.020. View

Sui H, Xiao S, Jiang S, Wu S, Lin H, Cheng L . Regorafenib induces NOX5-mediated endoplasmic reticulum stress and potentiates the anti-tumor activity of cisplatin in non-small cell lung cancer cells. Neoplasia. 2023; 39:100897. PMC: 10036942. DOI: 10.1016/j.neo.2023.100897. View

Pham T, Kumar K, DeCant B, Shang M, Munshi S, Matsangou M . Induction of MNK Kinase-dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors. Mol Cancer Ther. 2018; 18(2):235-244. PMC: 6363873. DOI: 10.1158/1535-7163.MCT-18-0768. View

Heeke A, Pishvaian M, Lynce F, Xiu J, Brody J, Chen W . Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol. 2018; 2018. PMC: 6139373. DOI: 10.1200/PO.17.00286. View

Grundy M, Buckanovich R, Bernstein K . Regulation and pharmacological targeting of RAD51 in cancer. NAR Cancer. 2020; 2(3):zcaa024. PMC: 7520849. DOI: 10.1093/narcan/zcaa024. View

10.

Shields M, Spaulding C, Metropulos A, Khalafalla M, Pham T, Munshi H . Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin. Cell Rep. 2022; 38(9):110441. PMC: 8989626. DOI: 10.1016/j.celrep.2022.110441. View

11.

Hadj Bachir E, Poiraud C, Paget S, Stoup N, El Moghrabi S, Duchene B . A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms. Biol Cell. 2021; 114(1):32-55. DOI: 10.1111/boc.202100003. View

12.

Wilhelm S, Dumas J, Adnane L, Lynch M, Carter C, Schutz G . Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2010; 129(1):245-55. DOI: 10.1002/ijc.25864. View

13.

Bruix J, Qin S, Merle P, Granito A, Huang Y, Bodoky G . Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2016; 389(10064):56-66. DOI: 10.1016/S0140-6736(16)32453-9. View

14.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall M . Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019; 381(4):317-327. PMC: 6810605. DOI: 10.1056/NEJMoa1903387. View

15.

Park W, Chen J, Chou J, Varghese A, Yu K, Wong W . Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clin Cancer Res. 2020; 26(13):3239-3247. PMC: 7380542. DOI: 10.1158/1078-0432.CCR-20-0418. View

16.

Ou D, Chen C, Hsu C, Chung C, Feng Z, Lee B . Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages. J Immunother Cancer. 2021; 9(3). PMC: 7986673. DOI: 10.1136/jitc-2020-001657. View

17.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

18.

Hu X, Wu L, Zhang Z, Chen M, Li Y, Zhang C . The anti-tumor effect of regorafenib in lung squamous cell carcinoma in vitro. Biochem Biophys Res Commun. 2018; 503(2):1123-1129. DOI: 10.1016/j.bbrc.2018.06.129. View

19.

Pham T, Shields M, Spaulding C, Principe D, Li B, Underwood P . Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers (Basel). 2021; 13(3). PMC: 7865443. DOI: 10.3390/cancers13030440. View

20.

Doleschel D, Hoff S, Koletnik S, Rix A, Zopf D, Kiessling F . Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J Exp Clin Cancer Res. 2021; 40(1):288. PMC: 8436536. DOI: 10.1186/s13046-021-02043-0. View